PEG-Asparaginase Based Multidrug Chemotherapy is Effective for Refractory Disseminated Extranodal NK/T-Cell Lymphoma With Leptomentigeal Involvement: A Clinical Case Report and Review of Literature

Hong Cheng, Tatyana Feldman, Kar F. Chow, Anthony Mato, David Panush, Xiao Yan Yang, Andre Goy, Fermina M. Mazzella, Pritish K. Bhattacharyya

Abstract


Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is an Epstein-Barr virus (EBV)-associated lymphoid malignancy derived from natural killer or cytotoxic T-cells. While many patients with early stage ENKTL can achieve complete remission after radiochemotherapy, patients with advanced stage, relapsed or refractory ENKTL usually respond poorly to conventional treatment. We present a case of ENKTL which did not respond to regular radiochemotherapy. One month after treatment, the disease progressed with dissemination to the mesenteric lymph nodes as well as central nervous system (CNS). However, the disease was effectively controlled by the addition of pegylated asparaginase (PEG-asparaginase), dexamethasone, and methotrexate to the regiment. Our data suggest that PEG-asparaginase based multidrug chemotherapy is a promising strategy to treat refractory and disseminated ENKTL involving the CNS.




doi: http://dx.doi.org/10.4021/jh60w


Keywords


Extranodal NK/T-cell lymphoma; PEG-asparaginase; Central nervous system

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)



This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
 

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!